Oscotec Inc (039200) Fair Value & Analysis
Healthcare · KR · Market cap 1.2T KRW
Fair value as of: Aug 13, 2026
From 24 valuation models · updated yesterday
Fair value updated Aug 13, 2026, revised from 25,062 KRW to 33,210 KRW (+32.5%) since Jul 12, 2026. Share price +20.5% over the past month.
A solid business, but screening 11% overvalued on our models.
What matters now
- A fairly wide model range (21,708 KRW to 52,707 KRW) leaves room in how you read the outcome.
- Our model range runs from 21,708 KRW (bear) to 52,707 KRW (bull), base 33,210 KRW. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 72/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range 16,150 KRW – 62,000 KRW · fair‑value band 21,708 KRW – 52,707 KRW · the 37,400 KRW price screens above the 33,210 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Oscotec Inc (039200) currently trades at 37,400 KRW, while our model-based Fair Value estimate is 33,210 KRW, implying the stock looks roughly 11.2% overvalued today. The Quality Score stands at 72/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Trailing-twelve-month revenue stands at 4.8B KRW. Revenue grew 30.5% year over year. It earns a return on equity of 35.9%. Net debt stands at 293M KRW. Fundamentals as of Aug 13, 2026
Our scenario range runs from 21,708 KRW (bear case) to 52,707 KRW (bull case); at 37,400 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 43% below its 52-week high and 41% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -11% fair-value upside, at -11%, 039200 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (86,538 KRW) versus Asset-Based (4,323 KRW). Highest evidence: Growth DCF (80).
Notify me when 039200 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 72 · Market factors (momentum, volatility) 27
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell …
Full company description
Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Oscotec Inc reported revenue of 99.8B KRW in FY2025 versus 3.9B KRW in FY2021, a compound +124.9%/yr. Reported net income was 52.3B KRW in FY2025.
039200 screens 11% overvalued. Compare with Torrent Pharmaceuticals Limited →
Peer Group
Pharmaceuticals · 25 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Pharmaceuticals median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Torrent Pharmaceuticals Limited 500420 | ₹4,876 | ₹4,360 | -11% |
| GlaxoSmithKline Pharmaceuticals Limited 500660 | ₹2,620 | ₹1,452 | -45% |
| Caregen Co 214370 | 64,400 KRW | 7,277 KRW | -89% |
| ST Pharm Co 237690 | 107,000 KRW | 50,110 KRW | -53% |
| DongKook Pharmaceutical Co 086450 | 21,600 KRW | 31,283 KRW | +45% |
| Kolon Life Science Inc 102940 | 17,460 KRW | 37,129 KRW | +113% |
| Huons Global Co 084110 | 25,100 KRW | 58,482 KRW | +133% |
| BINEX Co 053030 | 7,300 KRW | 1,844 KRW | -75% |
| Anterogen.Co.,Ltd., a bio-venture company, 065660 | 15,520 KRW | 4,741 KRW | -69% |
| Kyung Dong Pharmaceutical Co 011040 | 5,180 KRW | 6,165 KRW | +19% |
Compare Oscotec Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Oscotec Inc (039200) overvalued or undervalued?
What is the fair value of 039200?
What is the quality score of 039200?
What is the revenue of Oscotec Inc (039200)?
What is the net profit margin of 039200?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Oscotec Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.